Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer.
暂无分享，去创建一个
J. Tabernero | N. Segal | M. Fakih | F. Ciardiello | J. Bendell | N. Tebbutt | A. Falcone | C. Eng | A. Sobrero | I. Chang | A. Uyei | M. Kozloff | M. Di Bartolomeo | Y. Yan | L. Roberts | T. Kim | Y. Shi | Niall C. Tebbutt | Fortunato Ciardiello | Cathy Eng | Yibing Yan | M. D. Bartolomeo | M. Fakih | Alfredo Falcone | Yi Shi | Ilsung Chang | Tae Hwan Kim